Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 4;15(1):92.
doi: 10.1186/s13014-020-01544-0.

Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Rosario Mazzola  1 , Barbara Alicja Jereczek-Fossa  2   3 , Davide Franceschini  4 , Slavisa Tubin  5 , Andrea Riccardo Filippi  6 , Maria Tolia  7 , Andrea Lancia  6 , Giuseppe Minniti  8 , Stefanie Corradini  9 , Stefano Arcangeli  10 , Marta Scorsetti  4 , Filippo Alongi  11   12
Affiliations
Review

Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Rosario Mazzola et al. Radiat Oncol. .

Abstract

Background: During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer.

Material and method: Narrative Review regarding retrospective and prospective studies published between January 2009 to November 2019 with at least 20 patients analyzed.

Results: Concerning the combination between SBRT and Immunotherapy, the correct sequence of remains uncertain, and seems to be drug-dependent. The optimal patients' selection is crucial to expect substantial benefits to SBRT/Immunotherapy combination and, among several factors. A potential field of interest is represented by the so-called oligoprogressed disease, in which SBRT could improve the long-term efficacy of the existing target therapy.

Conclusions: A low tumor burden seems to be the most relevant, thus making the oligometastatic disease represent the ideal setting for the use of combination therapies with immunological drugs.

Keywords: Immunotherapy; Metastases-directed therapy; Oligometastasis; Target therapy.

PubMed Disclaimer

Conflict of interest statement

Nothing to declare.

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi: 10.1200/JCO.1995.13.1.8. - DOI - PubMed
    1. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17(8):1100–1107. doi: 10.1634/theoncologist.2012-0092. - DOI - PMC - PubMed
    1. Mazzola R, Corradini S, Gregucci F, Figlia V, Fiorentino A, Alongi F. Role of radiosurgery/stereotactic radiotherapy in Oligometastatic disease: brain Oligometastases. Front Oncol. 2019;9:206. doi: 10.3389/fonc.2019.00206. - DOI - PMC - PubMed
    1. Alongi F, Mazzola R, Figlia V, Guckenberger M. Stereotactic body radiotherapy for lung oligometastases: literature review according to PICO criteria. Tumori. 2018;104(3):148–156. doi: 10.1177/0300891618766820. - DOI - PubMed
    1. Mazzola R, Fersino S, Ferrera G, Targher G, Figlia V, Triggiani L, et al. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Med Oncol. 2018;35(9):121. doi: 10.1007/s12032-018-1190-8. - DOI - PubMed